Xanthoma of the tendon - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Comprehensive Guide to Tendon Xanthoma

Tendon Xanthoma: A Complete Patient‑Focused Guide

Overview

Tendon xanthoma (also called xanthoma of the tendon) is a benign, cholesterol‑rich deposit that forms within the collagen fibers of large tendons—most commonly the Achilles tendon, extensor tendons of the hands, and the patellar tendon. The lesion feels like a firm, yellowish nodule that may be palpable under the skin. While the nodules are not cancerous, they often signal an underlying lipid disorder, particularly familial hypercholesterolemia (FH), and can be an early clue to premature atherosclerotic cardiovascular disease.

Who it affects: Tendon xanthomas are most frequent in adults aged 20‑50 years, with a strong male predominance (≈ 2–3 : 1). They are exceptionally rare in children, except when a severe FH mutation is present.

Prevalence: In the United States, FH affects about 1 in 250 people; of those, ~ 15‑20 % develop tendon xanthomas. Worldwide, an estimated 4–5 million individuals have tendon xanthomas associated with FH or other dyslipidemias.1

Symptoms

Tendon xanthomas are usually asymptomatic at first, but they may cause the following:

  • Visible nodules – yellow‑white, firm lumps along the tendon, most often on the Achilles, hands, elbows, or knees.
  • Palpable thickening – the affected tendon feels thicker or “rope‑like.”
  • Pain or discomfort – especially after prolonged activity, walking, or wearing tight shoes.
  • Reduced range of motion – if the nodule is large, ankle dorsiflexion or finger extension may be limited.
  • Skin changes – occasional overlying skin discoloration or ulceration if the nodule rubs against clothing.
  • Systemic signs of hyperlipidemia – many patients also have corneal arcus, xanthelasma (eyelid plaques), or a family history of early heart attacks.

Causes and Risk Factors

Underlying Mechanism

All tendon xanthomas result from the accumulation of foam cells – macrophages that have ingested low‑density lipoprotein (LDL) cholesterol. These cells cluster within the tendon’s extracellular matrix, forming the yellow nodules.

Major Causes

  • Familial Hypercholesterolemia (FH) – an autosomal dominant defect in the LDL‑receptor, ApoB, or PCSK9 genes. Untreated FH leads to lifelong elevation of LDL‑C (> 190 mg/dL in heterozygotes, > 300 mg/dL in homozygotes).
  • Secondary hyperlipidemia – uncontrolled diabetes, hypothyroidism, nephrotic syndrome, or chronic liver disease can raise LDL‑C enough to produce xanthomas.
  • Long‑term use of certain medications – e.g., cyclosporine, protease inhibitors, and some corticosteroids may increase serum cholesterol.

Risk Factors

  • Male sex (higher prevalence of tendon thickening).
  • Positive family history of premature coronary artery disease (CAD) or known FH.
  • Smoking – amplifies LDL oxidation and accelerates plaque formation.
  • Obesity and metabolic syndrome – contribute to secondary dyslipidemia.
  • Age > 20 years without lipid‑lowering therapy.

Diagnosis

The diagnosis combines a clinical exam, imaging, and laboratory evaluation.

1. Clinical Examination

  • Inspection for visible yellow nodules on tendons.
  • Palpation to assess firmness and size.
  • Documentation of distribution (Achilles, extensor tendons of the hands, patellar).

2. Laboratory Tests

  • Lipid panel – fasting total cholesterol, LDL‑C, HDL‑C, triglycerides.
  • Genetic testing for FH (LDLR, ApoB, PCSK9) when LDL‑C > 190 mg/dL with tendon xanthoma and/or family history.
  • Secondary causes: thyroid‑stimulating hormone (TSH), fasting glucose/HbA1c, renal function, liver enzymes.

3. Imaging Studies

  • Ultrasound – high‑resolution sonography shows hyperechoic, heterogeneous masses within the tendon.
  • MRI – provides detailed tissue characterization; xanthomas appear as well‑circumscribed, high‑signal lesions on T2‑weighted images.
  • CT scan – rarely needed, but can assess calcification if surgical planning is considered.

4. Histopathology (rare)

Biopsy is seldom required but, if performed, shows foamy macrophages and cholesterol clefts within the tendon matrix.

Treatment Options

Management targets two goals: (1) reduce the size or prevent growth of the xanthoma and (2) lower cardiovascular risk.

1. Lipid‑Lowering Medications

  • Statins – first‑line; reduce LDL‑C by 30‑50 % and can slow or mildly shrink existing xanthomas.2
  • Ezetimibe – added when LDL‑C goals are not met with maximally tolerated statin.
  • PCSK9 inhibitors (evolocumab, alirocumab) – monoclonal antibodies that can lower LDL‑C > 60 % and have been shown in case series to cause regression of tendon xanthomas over 2‑3 years.
  • Liver‑X‑receptor agonists (e.g., alirocumab‑related investigational agents) – under clinical trial; may directly reduce foam‑cell formation.

2. Lifestyle Interventions

  • Diet low in saturated fat and trans‑fat; emphasizing soluble fiber, plant sterols, and omega‑3 fatty acids.
  • Weight management – aim for BMI < 25 kg/m².
  • Regular aerobic exercise (≥150 min/week) to improve HDL‑C and overall cardiovascular health.
  • Avoid tobacco and limit alcohol.

3. Procedural Options

  • Surgical excision – considered for large, painful nodules that limit function; risk of tendon weakening or rupture must be discussed.
  • Liposuction‑assisted removal – minimally invasive, can improve cosmetic appearance but does not treat the underlying lipid disorder.
  • Laser‑assisted therapy – experimental; limited evidence.

4. Management of Secondary Causes

Treat hypothyroidism, diabetes, or nephrotic syndrome aggressively to lower LDL‑C levels.

Living with Tendon Xanthoma

Patients can lead active, normal lives with proper management.

  • Regular follow‑up – lipid panel every 3‑6 months until goals are met, then annually.
  • Self‑examination – monthly check for growth of nodules or new lesions; report changes promptly.
  • Footwear care – wear well‑fitted, cushioned shoes to reduce pressure on Achilles xanthomas and prevent skin breakdown.
  • Physical therapy – stretching and strengthening of affected tendons can preserve range of motion.
  • Family screening – first‑degree relatives should receive lipid testing and genetic counseling if FH is confirmed.
  • Medication adherence – use pill organizers or smartphone reminders; missing doses reduces efficacy and may allow xanthoma growth.

Prevention

Because tendon xanthomas are a manifestation of systemic lipid excess, primary prevention focuses on lifelong cardiovascular health.

  1. Identify FH early – cascade screening of relatives after a diagnosis.
  2. Start lipid‑lowering therapy promptly – guidelines recommend high‑intensity statin therapy in heterozygous FH from age 8‑10 years.
  3. Adopt a heart‑healthy diet – Mediterranean or DASH patterns have proven LDL‑C lowering effects.
  4. Maintain a healthy weight and stay active – regular exercise improves lipid profile and reduces tendon stress.
  5. Avoid tobacco – smoking accelerates atherosclerosis and may increase xanthoma formation.
  6. Regular medical review – annual physicals with lipid checks for high‑risk individuals.

Complications

If left untreated, tendon xanthomas can lead to several problems:

  • Progressive tendon thickening – may cause chronic pain, limited mobility, and higher risk of tendon rupture (especially Achilles).
  • Cardiovascular disease – the presence of tendon xanthoma is an independent predictor of premature coronary artery disease, myocardial infarction, and stroke.3
  • Psychosocial impact – visible nodules can cause anxiety, embarrassment, or body‑image concerns.
  • Skin ulceration – from friction or pressure over the nodule, leading to secondary infection.
  • Complications of surgery – if excision is performed, there is a risk of tendon weakening, infection, or scar formation.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe pain in the affected tendon that does not improve with rest – could indicate a tendon rupture.
  • Rapid swelling, redness, or warmth over a xanthoma plus fever – possible infection (cellulitis or abscess).
  • Chest pain, shortness of breath, or unexplained weakness – may be a sign of an acute cardiovascular event, which is more common in people with FH.
  • Loss of sensation or severe numbness in the foot/hand associated with a tendon xanthoma – could indicate nerve compression.

References

  1. Nordestgaard BG, et al. “Familial hypercholesterolaemia is underdiagnosed and undertreated in general practice.” European Heart Journal. 2020;41:1905‑1918.
  2. Stone NJ, et al. “2018 ACC/AHA Guideline on the Management of Blood Cholesterol.” Circulation. 2019;139:e1082‑e1143.
  3. Krauss RM. “Lipoprotein subfractions and cardiovascular disease.” Current Opinion in Lipidology. 2021;32:210‑218.
  4. Mayo Clinic. “Tendon xanthoma.” Accessed March 2024. https://www.mayoclinic.org
  5. World Health Organization. “Family hypercholesterolaemia (FH).” Fact sheet, 2023.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References